ArticleJournal of virology2013
The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 97 citations in OpenAlex.
- BTP2 restricts Tulane virus and human norovirus replication independent of store-operated calcium entry.Journal of virology · 2025Article
- Discovery of Small Molecules Targeting Norovirus 3CL Protease by Multi-Stage Virtual Screening.International journal of molecular sciences · 2025Article
- Identification of Co-29, a 5-cyano-2-thiacetyl aromatic pyrimidinone, as a potential inhibitor targeting the RdRp of norovirus.Virology journal · 2025Article
- Activity and cryo-EM structure of the polymerase domain of the human norovirus ProPol precursor.Journal of virology · 2024Article
- Human norovirus cultivation systems and their use in antiviral research.Journal of virology · 2024Review
- Infection of neonatal mice with the murine norovirus strain WU23 is a robust model to study norovirus pathogenesis.Lab animal · 2023Article
- Recent insights into reverse genetics of norovirus.Virus research · 2023Review
- Structural Investigations on Novel Non-Nucleoside Inhibitors of Human Norovirus Polymerase.Viruses · 2022Article
- Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection.Viruses · 2022Article
- The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.Molecules (Basel, Switzerland) · 2022Article
- Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of Resistance.Pharmaceuticals (Basel, Switzerland) · 2021Article
- A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo.Viruses · 2021Article
- Structure-Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections.Microorganisms · 2021Article
- Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.Microorganisms · 2021Review
- Design, development, and validation of a strand-specific RT-qPCR assay for GI and GII human Noroviruses.Wellcome open research · 2021Article
- Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase.Journal of chemical information and modeling · 2020Article
- Article
- A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase.Scientific reports · 2019Article
- Astrovirus replication in human intestinal enteroids reveals multi-cellular tropism and an intricate host innate immune landscape.PLoS pathogens · 2019Article
- A robust human norovirus replication model in zebrafish larvae.PLoS pathogens · 2019Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human noroviruses are a major cause of food-borne illness, accountable for 50% of all-etiologies outbreaks of acute gastroenteritis (in both developing and developed countries). There is no vaccine or antiviral drug for the prophylaxis or treatment of norovirus-induced gastroenteritis. We recently reported the inhibitory effect of 2'-C-methylcytidine (2CMC), a hepatitis C virus polymerase inhibitor, on the in vitro replication of murine norovirus (MNV). Here we evaluated the inhibitory effect of 2CMC on in vitro human norovirus replication through a Norwalk virus replicon model and in a mouse model by using AG129 mice orally infected with MNV. Survival, weight, and fecal consistency were monitored, and viral loads in stool samples and organs were quantified. Intestines were examined histologically. 2CMC reduced Norwalk virus replicon replication in a dose-dependent manner and was able to clear cells of the replicon. Treatment of MNV-infected AG129 mice with 2CMC (i) prevented norovirus-induced diarrhea; (ii) markedly delayed the appearance of viral RNA and reduced viral RNA titers in the intestine, mesenteric lymph nodes, spleen, lungs, and stool; (iii) completely prevented virus-induced mortality; and (iv) resulted in protective immunity against a rechallenge. We demonstrate for the first time that a small-molecule inhibitor of norovirus replication protects from virus-induced disease and mortality in a relevant animal model. These findings pave the way for the development of potent and safe antivirals as prophylaxis and therapy of norovirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.